SEC 13F Intelligence

Orbimed Advisors LLC / ALNY

Orbimed Advisors LLC’s Alnylam Pharmaceuticals Inc Position

Does Orbimed Advisors LLC own Alnylam Pharmaceuticals Inc (ALNY)? Yes — 119.0K shares worth $39M (+0.78% of its 13F portfolio) as of Q1 2026, down from 288.8K shares the prior filed quarter.

Position Value
$39M
Q1 2026
Shares
119.0K
% of Portfolio
+0.78%
Quarters Held
10
currently held

Position History ALNY

Reported value by quarter
Q3 ’22: $50MQ3 ’22Q4 ’23: $15MQ2 ’24: $61MQ2 ’24Q3 ’24: $69MQ4 ’24: $98MQ4 ’24Q1 ’25: $93MQ2 ’25: $111MQ2 ’25Q3 ’25: $138MQ4 ’25: $115MQ4 ’25Q1 ’26: $39Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026119.0K$39M+0.78%
Q4 2025288.8K$115M+2.34%
Q3 2025301.6K$138M+3.23%
Q2 2025341.9K$111M+2.78%
Q1 2025346.1K$93M+2.23%
Q4 2024415.6K$98M+2.01%
Q3 2024250.3K$69M+1.25%
Q2 2024250.3K$61M+1.20%
Q4 202379.4K$15M+0.30%
Q3 2022250.5K$50M+0.93%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Orbimed Advisors LLC’s full portfolio or all institutional holders of ALNY.